CT-707

Shouyao Holdings (Beijing) Co. LTD · Phase 1 active Small molecule

At a glance

Generic name	CT-707
Also known as	CT-707 tablet, SY-707 tablet, Conteltinib, CT-707 granules
Sponsor	Shouyao Holdings (Beijing) Co. LTD
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Study of SY-5933 Plus CT-707 in Advanced Solid Tumors With KRAS p.G12C Mutation (PHASE1, PHASE2)
Safety, Pharmacokinetics and Efficacy of CT-707, Toripalimab and Gemcitabine in Advanced Pancreatic Cancer (PHASE1, PHASE2)
Study of Safety, Efficacy and Pharmacokinetics of CT-707 in Patients With ALK-positive Non-small Cell Lung Cancer (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

CT-707 CI brief — competitive landscape report
CT-707 updates RSS · CI watch RSS
Shouyao Holdings (Beijing) Co. LTD portfolio CI